Piper Sandler Increases STERIS (NYSE:STE) Price Target to $200.00

STERIS (NYSE:STEGet Rating) had its price target boosted by stock analysts at Piper Sandler from $197.00 to $200.00 in a research report issued on Friday, The Fly reports. Piper Sandler’s target price would suggest a potential downside of 5.15% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. StockNews.com assumed coverage on shares of STERIS in a research report on Thursday, March 16th. They issued a “buy” rating for the company. KeyCorp upped their price objective on shares of STERIS from $210.00 to $235.00 in a research report on Friday. TheStreet raised shares of STERIS from a “c” rating to a “b-” rating in a research report on Wednesday. JMP Securities reduced their price target on shares of STERIS from $250.00 to $240.00 and set a “market outperform” rating on the stock in a research report on Wednesday, February 15th. Finally, Stephens reaffirmed an “overweight” rating and set a $220.00 price target on shares of STERIS in a research report on Thursday, February 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $226.40.

STERIS Trading Up 1.4 %

Shares of STE opened at $210.85 on Friday. The stock has a fifty day moving average of $187.26 and a two-hundred day moving average of $187.64. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.61 and a current ratio of 2.48. The company has a market capitalization of $20.93 billion, a PE ratio of 197.06, a price-to-earnings-growth ratio of 1.97 and a beta of 0.85. STERIS has a fifty-two week low of $159.21 and a fifty-two week high of $236.10.

STERIS (NYSE:STEGet Rating) last released its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.15. The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a positive return on equity of 12.86% and a negative net margin of 0.58%. During the same period in the prior year, the firm posted $2.04 EPS. As a group, analysts forecast that STERIS will post 8.05 EPS for the current year.

Institutional Trading of STERIS

Institutional investors have recently bought and sold shares of the company. 1832 Asset Management L.P. acquired a new position in STERIS in the first quarter worth approximately $25,000. Delta Asset Management LLC TN bought a new position in STERIS in the fourth quarter worth $27,000. Fiduciary Alliance LLC bought a new position in STERIS in the fourth quarter worth $28,000. Asset Dedication LLC acquired a new position in STERIS during the fourth quarter worth $30,000. Finally, Pinnacle Financial Partners Inc. acquired a new position in STERIS during the third quarter worth $33,000. Institutional investors and hedge funds own 92.35% of the company’s stock.

STERIS Company Profile

(Get Rating)

STERIS Plc engages in the provision of healthcare and life science product and service solutions. It operates through the following segments: Healthcare, Life Sciences, Applied Sterilization Technologies, and Dental. The Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites.

Featured Articles

The Fly logo

Analyst Recommendations for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.